• Patrícia Marques Fortes, Ricardo Vieira Teles Filho, Lucas Henrique Souza de Azevêdo, Victória Coelho Jácome Queiroz, and Costa Paulo Sérgio Sucasas da PSSD http://orcid.org/0000-0001-9370-9139 Departamento de Pediatria, Hospital das Clínicas, Faculdade de Medicina, Unive.
• Departamento de Pediatria, Hospital das Clínicas, Faculdade de Medicina, Universidade Federal de Goiás (UFG), Goiânia, Goiás, GO, Brasil.
• Rev Assoc Med Bras (1992). 2020 Nov 1; 66 (11): 1487-1492.

MethodsThis study aimed to evaluate the efficacy of the action of the Lactobacillus Plantarum probiotic as a immunomodulatory and hypolipidemic agent in dyslipidemic nephrotic children and adolescents. This is a randomized, double-blind, placebo-controlled clinical trial in pediatric, compensated or partially compensated nephrotic syndrome and dyslipidemic subjects undergoing regular outpatient follow-up. Serum lipid and TNF-α (proinflammatory) and IL-10 (anti-inflammatory) cytokine variations were evaluated. Cytokines were analyzed by enzyme-linked immunosorbent assay (ELISA).ResultsIn the probiotic group there was a tendency to reduce TNF-α levels and increase IL-10 levels when compared to controls. Regarding the lipid profile, there was a decrease in serum triglyceride (6.0 mg / dL) and total cholesterol (41.5 mg / dL) levels in the probiotic group when compared to baseline levels, while in the control group there was an increase in serum triglyceride (49.5 mg / dL) and total cholesterol (8.0 mg / dL) levels, respectively.ConclusionPreliminary results suggest that L. Plantarum showed an immunomodulatory and hypolipidemic effect in nephrotic and dyslipidemic pediatric subjects.

14 keywords...

hide…